Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ulipristal is a synthetic selective progesterone receptor modulator (SPRM) used primarily as an emergency contraceptive to prevent pregnancy after unprotected intercourse or contraceptive failure. It acts mainly by inhibiting or delaying ovulation through antagonistic and partial agonist effects at the progesterone receptor, thereby suppressing the luteinizing hormone surge necessary for follicular rupture. Ulipristal may also alter endometrial thickness, potentially affecting implantation, though its primary action is pre-fertilization. It is a derivative of 19-norprogesterone and has some affinity for glucocorticoid receptors but with lower activity than mifepristone. In some regions, it has also been approved for the treatment of uterine fibroids under different brand names[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ulipristal.